Enhancing FTS (Salirasib) efficiency via combinatorial treatment
Eya Wolfson1, Eran Schmukler, Sari Trangle Schokoroy
1Department of Neurobiology, Tel-Aviv University, Ramat-Aviv, Israel.
Abstract:
The Ras oncogene transmits signals, which regulate various cellular processes including cell motility, differentiation, growth and death. Since Ras signalling is abnormally activated in more than 30% of human cancers, Ras and its downstream signalling pathways are considered good targets for therapeutic interference. Ras is post-translationally modified by the addition of a farnesyl group, which permits its attachment to the plasma membrane. Exploiting this knowledge, a synthetic Ras inhibitor, S-trans, trans-farnesylthiosalicylic acid (FTS; Salirasib), was developed. FTS resembles the farnesylcysteine group of Ras, and acts as an effective Ras antagonist. In the present review, the effect of FTS in combination with various other drugs, as tested in vitro and in vivo, and its therapeutic potential are discussed. As reviewed, FTS cooperates with diverse therapeutic agents, which significantly improves treatment outcome. Therefore, combinations of FTS with other agents have a potential to serve as anti-cancer or anti-inflammatory therapies.
Insights
S-trans, trans-farnesylthiosalicylic acid (FTS) is a synthetic Ras inhibitor that shows promise in cancer therapy. FTS, when combined with other drugs, significantly improves treatment outcomes in preclinical studies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Ras oncogene signaling regulates critical cellular processes and is hyperactivated in over 30% of human cancers.
- Ras protein requires farnesylation for plasma membrane attachment, presenting a target for therapeutic intervention.
Purpose of the Study:
- To review the therapeutic potential of S-trans, trans-farnesylthiosalicylic acid (FTS; Salirasib), a synthetic Ras inhibitor.
- To evaluate the efficacy of FTS in combination with other agents in preclinical cancer models.
Main Methods:
- Review of in vitro and in vivo studies investigating FTS and its combinations.
- Analysis of FTS mechanism of action as a Ras antagonist.
Main Results:
- FTS acts as an effective Ras antagonist by mimicking the farnesylcysteine group.
- FTS demonstrates synergistic effects when combined with various therapeutic agents.
- Combinations involving FTS significantly enhance treatment outcomes in preclinical models.
Conclusions:
- FTS exhibits considerable therapeutic potential as an anti-cancer agent.
- Combination therapies involving FTS may offer improved anti-cancer and anti-inflammatory treatments.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers